D. Pardoll
Immunology · 2001–2023
A researcher in the Science corpus: 38 papers; trusts 40 researchers and is trusted by 114 researchers here, as inferred from the citation graph.
Subfields
- Immunology — 537 citations into it; #10 of 2,162 by trust here, #16 by citations
- Oncology — 504 citations into it; #2 of 1,698 by trust here, #7 by citations
- Molecular Biology — 149 citations into it
- Cancer Research — 83 citations into it
- Pathology and Forensic Medicine — 60 citations into it
- Biological Psychiatry — 8 citations into it
- Psychiatry and Mental health — 5 citations into it
Whom D. Pardoll trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- W. Zou
- L. Lanier
- G. Freeman
- J. Pollard
- Taku Okazaki
- M. Butte
- M. Karin
- M. Keir
- Véronique Baud
- Arlene H. Sharpe
Who trusts D. Pardoll overall
- K. Palucka
- M. Teng
- Antoni Ribas
- Erik Sahai
- W. Zou
- Jacques Banchereau
- Yuhui Huang
- S. Wei
- R. Barroso-Sousa
- Liufu Deng
Papers from D. Pardoll's perspective
Ordered by how strongly the researchers D. Pardoll trusts endorse each paper. Same corpus, a different order for every researcher.
- Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation (Nature Immunology)
- Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. (Science)
- Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma (Nature Medicine)
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation (Journal of Experimental Medicine)
- Coregulation of CD8+ T cell exhaustion during chronic viral infection by multiple inhibitory receptors (Nature Immunology)
- The B7 family revisited. (Annual Review of Immunology)
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (Proceedings of the National Academy of Sciences of the United States of America)
- Regulatory T cell lineage specification by the forkhead transcription factor foxp3. (Immunity)
Their papers
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis (2002) — 1,244 citations
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) — 1,526 citations
- Neoadjuvant checkpoint blockade for cancer immunotherapy (2020) — 879 citations
- Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria (2018) — 957 citations
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer (2018) — 1,781 citations
- Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade (2017) — 5,893 citations
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. (2016) — 1,115 citations
- Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer (2016) — 766 citations
- Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy (2016) — 2,482 citations
- Primary resistance to PD-1 blockade mediated by JAK1/2 mutations (2016) — 1,167 citations
- Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses (2015) — 917 citations
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) — 1,081 citations
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade (2015) — 665 citations
- Immune checkpoint blockade: a common denominator approach to cancer therapy (2015) — 3,868 citations
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency (2015) — 4,624 citations
- Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014) — 2,243 citations
- Microbiota organization is a distinct feature of proximal colorectal cancers (2014) — 627 citations
- Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma (2013) — 738 citations
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas (2013) — 859 citations
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012) — 2,143 citations